Fintel · Oct 31, 2026
NASDAQ · BSX
Boston Scientific Corporation
Healthcare · Medical - Devices
$45.82
Up+$2.32 (+5.33%)
Updated Nov 5, 2026, 6:38 AM
SID Score
5.4/10
Composite research score
Smart Money
62/100
Neutral
- Market cap
- 135.98B
- P/E ratio
- 48.75
- Dividend yield
- 0.00%
- 52-week range
- $39.57 – $100.90
- Volume
- 34.56M
- Avg. volume
- 9.87M
Price performance · BSX
BSX price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 4, 2026
BSX closed at $45.82 after 21 trading sessions, up 10.20% for the selected period.
- Last close
- $45.82
- Period change
- +10.20%
- Period low
- $41.58
- Period high
- $46.01
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 4, 2026 | $44.805 | $46.97 | $44.76 | $45.82 | 34.56M |
| Nov 3, 2026 | $43.87 | $44.615 | $43.21 | $43.50 | 18.89M |
| Nov 2, 2026 | $42.07 | $44.365 | $41.90 | $44.32 | 22.71M |
| Oct 30, 2026 | $42.95 | $43.29 | $41.725 | $41.98 | 22.47M |
| Oct 29, 2026 | $41.81 | $43.085 | $41.675 | $42.69 | 31.76M |
| Oct 28, 2026 | $41.95 | $43.915 | $39.57 | $42.43 | 69.84M |
| Oct 27, 2026 | $45.29 | $45.33 | $44.855 | $45.06 | 15.14M |
| Oct 26, 2026 | $45.31 | $46.07 | $45.125 | $45.58 | 11.93M |
| Oct 23, 2026 | $45.84 | $46.16 | $45.215 | $45.69 | 8.77M |
| Oct 22, 2026 | $44.72 | $46.05 | $44.62 | $46.01 | 16.4M |
| Oct 21, 2026 | $45.04 | $45.64 | $43.915 | $44.51 | 15.19M |
| Oct 20, 2026 | $45.67 | $46.045 | $45.15 | $45.58 | 16.01M |
| Oct 19, 2026 | $44.01 | $45.10 | $43.935 | $45.05 | 13.97M |
| Oct 16, 2026 | $44.45 | $44.8314 | $43.89 | $44.39 | 12.41M |
| Oct 15, 2026 | $43.945 | $44.43 | $43.46 | $44.14 | 15.87M |
| Oct 14, 2026 | $43.40 | $43.5785 | $42.28 | $43.00 | 15.1M |
| Oct 13, 2026 | $43.95 | $44.1522 | $42.455 | $43.31 | 14.28M |
| Oct 12, 2026 | $43.10 | $43.92 | $42.67 | $43.84 | 13.6M |
| Oct 9, 2026 | $42.12 | $42.83 | $41.97 | $42.73 | 13.04M |
| Oct 8, 2026 | $41.50 | $42.27 | $41.385 | $42.04 | 22.88M |
| Oct 7, 2026 | $42.19 | $42.515 | $41.50 | $41.58 | 15.89M |
Latest BSX news
The latest Smart Investors Daily articles mentioning BSX.
Stock researchCompany · Overview
Company
Market Activity
Research & News
BSX research
Overview
Company profile and research snapshot.
Company profile
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for roughly 36% of the firm's total sales.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $127.00
- Implied upside
- —
- Analysts
- 24
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | TD Cowen | Hold | — |
| Oct 30, 2026 | Barclays | Equal-Weight | — |
| Oct 29, 2026 | UBS | Buy | — |
| Oct 29, 2026 | Leerink Partners | Outperform | — |
| Oct 29, 2026 | Citigroup | Neutral | — |
News briefing
No generated briefing is available yet.
Benzinga · Oct 30, 2026
TD Cowen Downgrades Boston Scientific to Hold, Lowers Price Target to $46
TD Cowen analyst Joshua Jennings downgrades Boston Scientific (NYSE:BSX) from Buy to Hold and lowers the price target from $56 to $46.
Benzinga · Oct 30, 2026
Barclays Maintains Equal-Weight on Boston Scientific, Lowers Price Target to $45
Barclays analyst Christopher Pasquale maintains Boston Scientific (NYSE:BSX) with a Equal-Weight and lowers the price target from $48 to $45.
Yahoo · Oct 29, 2026
Cyberattack Fallout Could Be A Game Changer For Boston Scientific (BSX)
Boston Scientific reported Q3 2026 sales of US$5,138 million and net income of US$582 million, alongside impairment charges and a reduced full year outlook after a prior cyberattack disrupted manufacturing and shipments. The updated guidance for a 1% to 3% decline in Q4 2026 sales, combined with softer performance in electrophysiology and WATCHMAN, places more pressure on Boston Scientific's broader portfolio and cost program to carry near term performance. The focus now turns to how Boston...
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
